These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 33002196)

  • 1. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions.
    Yu XB; Jiao Z; Zhang CH; Dai Y; Zhou ZY; Han L; Wen X; Sheng CC; Lin GY; Pan JY
    Br J Clin Pharmacol; 2021 Apr; 87(4):1869-1877. PubMed ID: 33002196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation.
    Ye Q; Wang Q; Chen W; Zhang R; Chen Z; Li P; Zhang X; Zhan Q; Wang C
    J Clin Pharm Ther; 2022 Oct; 47(10):1608-1618. PubMed ID: 35716048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis.
    Wang P; Liu S; Sun T; Yang J
    Int J Antimicrob Agents; 2024 Mar; 63(3):107099. PubMed ID: 38280575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
    Hanafin PO; Kwa A; Zavascki AP; Sandri AM; Scheetz MH; Kubin CJ; Shah J; Cherng BPZ; Yin MT; Wang J; Wang L; Calfee DP; Bolon M; Pogue JM; Purcell AW; Nation RL; Li J; Kaye KS; Rao GG
    Clin Microbiol Infect; 2023 Sep; 29(9):1174-1181. PubMed ID: 37217076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of polymyxin B in patients with liver dysfunction.
    Li X; Cheng Y; Chen B; Chen Y; Huang Y; Zhang B; Que W; Liu M; Zhang H; Qiu H
    Br J Clin Pharmacol; 2023 Dec; 89(12):3561-3572. PubMed ID: 37461291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Linezolid Dose Adjustment for Creatinine Clearance in Critically Ill Patients: A Multicenter, Prospective, Open-Label, Observational Study.
    Wang X; Wang Y; Yao F; Chen S; Hou Y; Zheng Z; Luo J; Qiu B; Li Z; Wang Y; Wu Z; Lan J; Chen C
    Drug Des Devel Ther; 2021; 15():2129-2141. PubMed ID: 34040351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.
    Tang T; Li Y; Xu P; Zhong Y; Yang M; Ma W; Xiang D; Zhang B; Zhou Y
    Crit Care; 2023 Apr; 27(1):164. PubMed ID: 37106370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
    Lakota EA; Landersdorfer CB; Nation RL; Li J; Kaye KS; Rao GG; Forrest A
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study.
    Cai XJ; Chen Y; Zhang XS; Wang YZ; Zhou WB; Zhang CH; Wu B; Song HZ; Yang H; Yu XB
    Front Pharmacol; 2022; 13():1019411. PubMed ID: 36313312
    [No Abstract]   [Full Text] [Related]  

  • 14. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients.
    Miglis C; Rhodes NJ; Avedissian SN; Kubin CJ; Yin MT; Nelson BC; Pai MP; Scheetz MH
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Pharmacodynamics, and Dose Optimization of Cefiderocol during Continuous Renal Replacement Therapy.
    Wenzler E; Butler D; Tan X; Katsube T; Wajima T
    Clin Pharmacokinet; 2022 Apr; 61(4):539-552. PubMed ID: 34792787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients.
    Pi MY; Cai CJ; Zuo LY; Zheng JT; Zhang ML; Lin XB; Chen X; Zhong GP; Xia YZ
    J Antimicrob Chemother; 2023 Mar; 78(3):792-801. PubMed ID: 36702748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.
    Wang P; Zhang Q; Zhu Z; Pei H; Feng M; Sun T; Yang J; Zhang X
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.
    Thamlikitkul V; Dubrovskaya Y; Manchandani P; Ngamprasertchai T; Boonyasiri A; Babic JT; Tam VH
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.